Patents Represented by Attorney, Agent or Law Firm Alan J. Grant
  • Patent number: 6368636
    Abstract: A method of reducing an immune response to a transplant in a recipient by treating said recipient with an amount of mesenchymal stem cells effective to reduce or inhibit host rejection of the transplant. The mesenchymal stem cells can be administered before, at the same time as, or after the transplant. Also disclosed is a method of inducing a reduced immune response against a host by foreign tissue, i.e., graft versus host disease, by treatment with mesenchymal stem cells.
    Type: Grant
    Filed: October 26, 1999
    Date of Patent: April 9, 2002
    Assignee: Osiris Therapeutics, Inc.
    Inventors: Kevin R. McIntosh, Joseph D. Mosca, Elena N. Klyushnenkova
  • Patent number: 6358702
    Abstract: This invention relates to newly identified polynucleotides, polypeptides encoded by such polynucleotides, the use of such polynucleotides and polypeptides, as well as the production of such polynucleotides and polypeptides. More particularly, the polypeptides of the present invention are human Hox C10 polypeptides. The invention also relates to identifying mesenchymal stem cells (MSCs) or other cells comprising such polypeptides or polynucleotides that encode the polypeptides.
    Type: Grant
    Filed: October 2, 1998
    Date of Patent: March 19, 2002
    Assignee: Osiris Therapeutics, Inc.
    Inventor: Timothy Connolly
  • Patent number: 6355239
    Abstract: Methods and devices using non-autologous mesenchymal stem cells comprising treating a recipient in need thereof with an effective amount of non-autologous mesenchymal stem cells, including methods and preparations for treating and regenerating connective tissue and enhancing bone marrow engraftment in an individual; and for using genetically engineered allogeneic human mesenchymal stem cells that carry within them genes of interest particularly for the expression of physiologically or pharmacologically active proteins in gene therapy for correction of genetic disorders or “rebuilding” proteins important in tissue repair.
    Type: Grant
    Filed: March 12, 1999
    Date of Patent: March 12, 2002
    Assignee: Osiris Therapeutics, Inc.
    Inventors: Scott P. Bruder, Kevin R. McIntosh, Daniel R. Marshak, Joseph D. Mosca
  • Patent number: 6344333
    Abstract: The present invention relates to an apparatus to perform reagent-free assays, which apparatus utilizes an all solid probe having an enzyme label that acts on a substrate by obtaining electrons directly from the electrode by bioelectrocatalysis.
    Type: Grant
    Filed: September 8, 1998
    Date of Patent: February 5, 2002
    Assignee: Synectig Corporation
    Inventor: Andrei L. Gindilis
  • Patent number: 6342370
    Abstract: This invention relates to newly identified polynucleotides, polypeptides encoded by such polynucleotides, the use of such polynucleotides and polypeptides, as well as the production of such polynucleotides and polypeptides. More particularly, the polypeptides of the present invention are human slit polypeptides. The invention also relates to identifying mesenchymal stem cells (MSCs) or other cells comprising such polypeptides or polynucleotides that encode the polypeptides.
    Type: Grant
    Filed: October 29, 1998
    Date of Patent: January 29, 2002
    Assignee: Osiris Therapeutics, Inc.
    Inventors: Timothy Connolly, Bhanu Rajput
  • Patent number: 6337388
    Abstract: This invention relates to newly identified auxotrophs, polynucleotides, polypeptides encoded by such polynucleotides, the use of such polynucleotides and polypeptides, as well as the production and isolation of such polynucleotides and polypeptides. More particularly, the polynucleotides and polypeptides of the present invention have been putatively identified as being very important to the growth and/or reproduction of Aspergillus fumigatus.
    Type: Grant
    Filed: February 4, 2000
    Date of Patent: January 8, 2002
    Assignee: Millenium Pharmaceuticals, Inc.
    Inventor: Vicky Gavrias
  • Patent number: 6328960
    Abstract: Disclosed is a method of reducing an immune response to a transplant in a recipient by treating said recipient with an amount of mesenchymal stem cells effective to reduce or inhibit host rejection of the transplant. The mesenchymal stem cells can be administered before, at the same time as, or after the transplant. Also disclosed is a method of inducing a reduced immune response against a host by foreign tissue, i.e., graft versus host disease, by treatment with mesenchymal stem cells.
    Type: Grant
    Filed: March 12, 1999
    Date of Patent: December 11, 2001
    Assignee: Osiris Therapeutics, Inc.
    Inventors: Kevin R. McIntosh, Joseph D. Mosca, Elena N. Klyushnenkova
  • Patent number: 6323009
    Abstract: Processes for the amplification of target DNA sequences in the form of single or double stranded circular DNA molecules, especially those present in colony and plaque extracts, using multiple specific and/or random sequence oligonucleotide primers are disclosed along with methods for detecting such amplified target sequences. A kit containing components for use in the invention is also described.
    Type: Grant
    Filed: June 28, 2000
    Date of Patent: November 27, 2001
    Assignee: Molecular Staging, Inc.
    Inventors: Roger S. Lasken, Frank B. Dean, John Nelson
  • Patent number: 6291187
    Abstract: Methods for the amplification of selected nucleic acids at high rate but with high specificity and control are disclosed using a secondary, tertiary, quaternary or higher order platform especially designed to amplify selected sequences within the primary product of linear or exponential rolling circle amplification and amplifying said sequences along with specialized detector or reporter molecules that serve to enhance the ability to detect the amplification products.
    Type: Grant
    Filed: May 24, 2000
    Date of Patent: September 18, 2001
    Assignee: Molecular Staging, Inc.
    Inventors: Stephen Kingsmore, R. Steven Wiltshire, Jeremy P. Lambert
  • Patent number: 6261806
    Abstract: This invention relates to newly identified polynucleotides, polypeptides encoded by such polynucleotides, the use of such polynucleotides and polypeptides, as well as the production of such polynucleotides and polypeptides. More particularly, the polypeptides of the present invention are PERV-D env polypeptides. The invention also relates to detecting the presence of a porcine retrovirus in tissue comprising such polypeptides or polynucleotides that encode the polypeptides.
    Type: Grant
    Filed: August 18, 1999
    Date of Patent: July 17, 2001
    Assignee: BioTransplant, Inc.
    Inventors: Papia T. Banerjee, Clive Patience, Goran K. Andersson
  • Patent number: 6090581
    Abstract: This invention relates to newly identified auxotrophs, polynucleotides, polypeptides encoded by such polynucleotides, the use of such polynucleotides and polypeptides, as well as the production and isolation of such polynucleotides and polypeptides. More particularly, the polynucleotides and polypeptides of the present invention have been putatively identified as being very important to the growth and/or reproduction of Aspergillus fumigatus.
    Type: Grant
    Filed: March 18, 1998
    Date of Patent: July 18, 2000
    Assignee: Millenium Pharmaceuticals, Inc.
    Inventor: Vicky Gavrias
  • Patent number: 5932624
    Abstract: A multiple vitamin supplement composition comprising folic acid and vitamin B.sub.12 disclosed that is essentially free of antioxidants is disclosed. The multiple vitamin supplement composition may contain vitamin B.sub.6. The multiple vitamin supplement composition is useful for lowering serum homocysteine levels to protect against related blood vessel disorders. Further disclosed is a method of preparing such a multiple vitamin supplement and a method of administration.
    Type: Grant
    Filed: October 17, 1995
    Date of Patent: August 3, 1999
    Inventor: Victor D. Herbert